Actinium Pharmaceuticals (NYSE:ATNM) Stock Price Up 6.2% – Still a Buy?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) shares were up 6.2% during trading on Thursday . The stock traded as high as $1.12 and last traded at $1.1050. Approximately 75,253 shares traded hands during trading, a decline of 38% from the average daily volume of 120,683 shares. The stock had previously closed at $1.04.

Actinium Pharmaceuticals Stock Down 4.5%

The stock’s 50 day moving average is $1.33 and its two-hundred day moving average is $1.46. The company has a market capitalization of $33.07 million, a PE ratio of -0.76 and a beta of -0.30.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. North Star Asset Management Inc. boosted its position in Actinium Pharmaceuticals by 100.0% during the second quarter. North Star Asset Management Inc. now owns 20,000 shares of the company’s stock valued at $28,000 after purchasing an additional 10,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in Actinium Pharmaceuticals by 0.9% in the third quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock valued at $2,215,000 after acquiring an additional 12,703 shares in the last quarter. Mayport LLC purchased a new position in Actinium Pharmaceuticals in the third quarter worth $35,000. AM Investment Strategies LLC acquired a new position in shares of Actinium Pharmaceuticals during the fourth quarter worth $40,000. Finally, Bank of America Corp DE boosted its position in shares of Actinium Pharmaceuticals by 76.6% in the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after purchasing an additional 34,176 shares in the last quarter. 27.50% of the stock is owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.